Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Commentary, Endocrinol Diabetes Res Vol: 1 Issue: 2
Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis
| Moulinath Banerjee1,2* | |
| 1Consultant Physician: Bolton NHS Foundation Trust, Minerva Road, Bolton UK BL4 0JR, United Kingdom | |
| 2Honorary Clinical Lecturer, Diabetes & Endocrine Research Group, Manchester University, Oxford Road M13 9RT, United Kingdom | |
| Corresponding author : Dr. Moulinath Banerjee Honorary Clinical Lecturer, Diabetes & Endocrine Research Group, Manchester University, Oxford Road M13 9RT, United Kingdom Tel: 01204 390583 Fax: 01204 390552 E-mail: moulinath.banerjee@manchester.ac.uk |
|
| Received: June 26, 2015 Accepted: August 26, 2015 Published: August 30, 2015 | |
| Citation: Banerjee M (2015) Potential Mechanism of SGLT2i Induced Euglycaemic Diabetic Ketoacidosis. Endocrinol Diabetes Res 1:2. doi:10.4172/2470-7570.1000107 | |
Abstract
Sodium glucose co-transporter 2 inhibitors are a new group of drugs available to treat patients with type 2 diabetes mellitus. Recently, FDA has sounded a warning of higher risk of Diabetes ketoacidosis among patients treated with this group of agents. This article reviews the available evidence to build a potential hypothesis to explain the development of this complication.
